# TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

> **NCT03899415** · PHASE1 · UNKNOWN · sponsor: **Beijing 302 Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** TCR redirected T cells

## Key facts

- **NCT ID:** NCT03899415
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-20
- **Primary completion:** 2022-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2019-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03899415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03899415, "TCR-Redirected T Cells Therapy in Patient With HBV Related HCC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03899415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*